Genetics of pancreatic neuroendocrine tumors: implications for the clinic
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetics of pancreatic neuroendocrine tumors: implications for the clinic
Authors
Keywords
-
Journal
Expert Review of Gastroenterology & Hepatology
Volume 9, Issue 11, Pages 1407-1419
Publisher
Informa UK Limited
Online
2015-09-29
DOI
10.1586/17474124.2015.1092383
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
- (2015) Olca Basturk et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives
- (2015) Silvia Ortolani et al. Future Oncology
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
- (2015) Timothy J. Hobday et al. JOURNAL OF CLINICAL ONCOLOGY
- Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors
- (2015) James C. Yao et al. PANCREAS
- Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines
- (2015) Ganesh K. Boora et al. Cancer Genetics
- Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
- (2015) V. Neychev et al. BMJ Open
- Neuroendocrine Tumors of the Pancreas: Current Concepts and Controversies
- (2014) Michelle D. Reid et al. ENDOCRINE PATHOLOGY
- Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) – A phase II non-randomised trial
- (2014) Michel Ducreux et al. EUROPEAN JOURNAL OF CANCER
- Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
- (2014) Susumu Hijioka et al. JOURNAL OF GASTROENTEROLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors
- (2014) R. Ohki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
- (2013) Michael Gnant et al. Breast Care
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine Tumors
- (2013) Ilaria Marinoni et al. GASTROENTEROLOGY
- The Genetics of Neuroendocrine Tumors
- (2013) Kjell Öberg SEMINARS IN ONCOLOGY
- Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib
- (2013) Aaron I. Vinik et al. Therapeutic Advances in Gastroenterology
- Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
- (2012) Shinichi Yachida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
- (2012) H. Sorbye et al. ANNALS OF ONCOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
- (2012) D. Speisky et al. CLINICAL CANCER RESEARCH
- Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
- (2012) Roeland F de Wilde et al. MODERN PATHOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
- (2012) Massimo Falconi et al. NEUROENDOCRINOLOGY
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression
- (2011) Francesco Panzuto et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Altered Telomeres in Tumors with ATRX and DAXX Mutations
- (2011) C. M. Heaphy et al. SCIENCE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
- (2010) Robert T. Jensen et al. CANCER
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions
- (2010) Aaron D. Goldberg et al. CELL
- MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases
- (2010) Vincenzo Corbo et al. ENDOCRINE-RELATED CANCER
- Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy
- (2010) Kjell E. Öberg et al. GASTROENTEROLOGY
- Periampullary and Duodenal Neoplasms in Neurofibromatosis Type 1: Two Cases and an Updated 20-Year Review of the Literature Yielding 76 Cases
- (2010) Daniel Relles et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres
- (2010) P. W. Lewis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Primary Lymph Node Gastrinoma or Occult Duodenal Microgastrinoma With Lymph Node Metastases in a MEN1 Patient
- (2009) Martin Anlauf et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors
- (2009) A M Schmitt et al. ENDOCRINE-RELATED CANCER
- Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential
- (2009) Arne Warth et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Pancreatic Tumors in von Hippel-Lindau Disease
- (2009) Olivier Corcos et al. PANCREAS
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients
- (2009) Pierre Goudet et al. WORLD JOURNAL OF SURGERY
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
- (2008) T. R. Halfdanarson et al. ANNALS OF ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search